Opportunities and challenges for the use of induced pluripotent stem cells in modelling neurodegenerative disease

Adult-onset neurodegenerative diseases are among the most difficult human health conditions to model for drug development. Most genetic or toxin-induced cell and animal models cannot faithfully recapitulate pathology in disease-relevant cells, making it excessively challenging to explore the potenti...

Full description

Bibliographic Details
Main Authors: Yi-Ying Wu, Feng-Lan Chiu, Chan-Shien Yeh, Hung-Chih Kuo
Format: Article
Language:English
Published: The Royal Society 2019-01-01
Series:Open Biology
Subjects:
Online Access:https://royalsocietypublishing.org/doi/pdf/10.1098/rsob.180177
id doaj-fbcbd12ab38945678e22b75a87206a1c
record_format Article
spelling doaj-fbcbd12ab38945678e22b75a87206a1c2020-11-25T03:59:37ZengThe Royal SocietyOpen Biology2046-24412019-01-019110.1098/rsob.180177180177Opportunities and challenges for the use of induced pluripotent stem cells in modelling neurodegenerative diseaseYi-Ying WuFeng-Lan ChiuChan-Shien YehHung-Chih KuoAdult-onset neurodegenerative diseases are among the most difficult human health conditions to model for drug development. Most genetic or toxin-induced cell and animal models cannot faithfully recapitulate pathology in disease-relevant cells, making it excessively challenging to explore the potential mechanisms underlying sporadic disease. Patient-derived induced pluripotent stem cells (iPSCs) can be differentiated into disease-relevant neurons, providing an unparalleled platform for in vitro modelling and development of therapeutic strategies. Here, we review recent progress in generating Alzheimer's, Parkinson's and Huntington's disease models from patient-derived iPSCs. We also describe novel discoveries of pathological mechanisms and drug evaluations that have used these patient iPSC-derived neuronal models. Additionally, current human iPSC technology allows researchers to model diseases with 3D brain organoids, which are more representative of tissue architecture than traditional neuronal cultures. We discuss remaining challenges and emerging opportunities for the use of three-dimensional brain organoids in modelling brain development and neurodegeneration.https://royalsocietypublishing.org/doi/pdf/10.1098/rsob.180177neurodegenerative diseasealzheimer's diseasebrain organoidhuntington's diseaseinduced pluripotent stem cellsparkinson's disease
collection DOAJ
language English
format Article
sources DOAJ
author Yi-Ying Wu
Feng-Lan Chiu
Chan-Shien Yeh
Hung-Chih Kuo
spellingShingle Yi-Ying Wu
Feng-Lan Chiu
Chan-Shien Yeh
Hung-Chih Kuo
Opportunities and challenges for the use of induced pluripotent stem cells in modelling neurodegenerative disease
Open Biology
neurodegenerative disease
alzheimer's disease
brain organoid
huntington's disease
induced pluripotent stem cells
parkinson's disease
author_facet Yi-Ying Wu
Feng-Lan Chiu
Chan-Shien Yeh
Hung-Chih Kuo
author_sort Yi-Ying Wu
title Opportunities and challenges for the use of induced pluripotent stem cells in modelling neurodegenerative disease
title_short Opportunities and challenges for the use of induced pluripotent stem cells in modelling neurodegenerative disease
title_full Opportunities and challenges for the use of induced pluripotent stem cells in modelling neurodegenerative disease
title_fullStr Opportunities and challenges for the use of induced pluripotent stem cells in modelling neurodegenerative disease
title_full_unstemmed Opportunities and challenges for the use of induced pluripotent stem cells in modelling neurodegenerative disease
title_sort opportunities and challenges for the use of induced pluripotent stem cells in modelling neurodegenerative disease
publisher The Royal Society
series Open Biology
issn 2046-2441
publishDate 2019-01-01
description Adult-onset neurodegenerative diseases are among the most difficult human health conditions to model for drug development. Most genetic or toxin-induced cell and animal models cannot faithfully recapitulate pathology in disease-relevant cells, making it excessively challenging to explore the potential mechanisms underlying sporadic disease. Patient-derived induced pluripotent stem cells (iPSCs) can be differentiated into disease-relevant neurons, providing an unparalleled platform for in vitro modelling and development of therapeutic strategies. Here, we review recent progress in generating Alzheimer's, Parkinson's and Huntington's disease models from patient-derived iPSCs. We also describe novel discoveries of pathological mechanisms and drug evaluations that have used these patient iPSC-derived neuronal models. Additionally, current human iPSC technology allows researchers to model diseases with 3D brain organoids, which are more representative of tissue architecture than traditional neuronal cultures. We discuss remaining challenges and emerging opportunities for the use of three-dimensional brain organoids in modelling brain development and neurodegeneration.
topic neurodegenerative disease
alzheimer's disease
brain organoid
huntington's disease
induced pluripotent stem cells
parkinson's disease
url https://royalsocietypublishing.org/doi/pdf/10.1098/rsob.180177
work_keys_str_mv AT yiyingwu opportunitiesandchallengesfortheuseofinducedpluripotentstemcellsinmodellingneurodegenerativedisease
AT fenglanchiu opportunitiesandchallengesfortheuseofinducedpluripotentstemcellsinmodellingneurodegenerativedisease
AT chanshienyeh opportunitiesandchallengesfortheuseofinducedpluripotentstemcellsinmodellingneurodegenerativedisease
AT hungchihkuo opportunitiesandchallengesfortheuseofinducedpluripotentstemcellsinmodellingneurodegenerativedisease
_version_ 1724453851870789632